Revenue: As of FY2026 Q2, the actual value is USD 0, missing the estimate of USD 4.296 M.

Cash, Cash Equivalents, and Marketable Securities

Gossamer Bio, Inc. estimated its cash, cash equivalents, and marketable securities to be approximately $57.0 million as of June 30, 2026.

Rights Reacquisition Agreement Financials

Gossamer Bio, Inc. entered into a Rights Reacquisition Agreement with Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. on July 23, 2026, terminating a previous Collaboration and License Agreement dated May 3, 2024. Under this new agreement, Chiesi will pay Gossamer Bio, Inc. a one-time, non-refundable, non-creditable payment of $5 million within 10 days as reimbursement for outstanding development costs, settling all of Chiesi’s outstanding or future payment obligations under the CLA. Gossamer Bio, Inc. made no upfront cash payment to reacquire the worldwide rights to seralutinib.

In consideration, Gossamer Bio, Inc. has agreed to make one-time, non-refundable, non-creditable milestone payments to Chiesi upon the first achievement of certain regulatory and commercial milestone events, with aggregate amounts capped. Gossamer Bio, Inc. will also pay Chiesi a royalty equal to a redacted percentage of worldwide Net Sales of Licensed Products, commencing on the First Commercial Sale, until the aggregate royalties reach a redacted Royalty Cap. Both parties are released from all obligations to share Development Costs and future profit- and loss-sharing rights and obligations, effective from the Rights Reacquisition Effective Date. All licenses granted under Article 3 of the CLA are terminated, and the non-compete covenant in Section 3.4 of the CLA also terminates. Chiesi will assign certain patent rights, product marks, regulatory filings, and documentation for the Existing Licensed Product to Gossamer Bio, Inc. and grant an irrevocable license under Chiesi Know-How.

Debt Restructuring

Gossamer Bio, Inc. completed an exchange of approximately $181.1 million of its 5.00% Convertible Senior Notes due 2027. This exchange was for approximately $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, along with applicable equity securities and warrants. The transaction reduced the aggregate principal amount of the Company’s debt by approximately $115.9 million, bringing the outstanding balance of the 2027 Notes to approximately $18.9 million.

Operational Outlook and Guidance

Gossamer Bio, Inc. plans to submit a New Drug Application (NDA) for seralutinib for the treatment of patients with Pulmonary Arterial Hypertension (PAH) in September 2026, following a Pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA). The FDA characterized the statistical significance and magnitude of the treatment effect observed in the PROSERA study as review issues rather than filing issues. Potential FDA approval could occur in the third quarter of 2027 if the NDA is accepted for filing. The Company also expects to effect a reverse stock split in or promptly following the third quarter of 2026, subject to final Board action.